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AbstrACt
Introduction People with type 2 diabetes (T2D) can 
improve glycaemic control or even achieve remission 
through weight loss and reduce their use of medication 
and risk of cardiovascular disease. The Glucose Lowering 
through Weight management (GLoW) trial will evaluate 
whether a tailored diabetes education and behavioural 
weight management programme (DEW) is more effective 
and cost- effective than a diabetes education (DE) 
programme in helping people with overweight or obesity 
and a recent diagnosis of T2D to lower their blood glucose, 
lose weight and improve other markers of cardiovascular 
risk.
Methods and analysis This study is a pragmatic, 
randomised, single- blind, parallel group, two- arm, 
superiority trial. We will recruit 576 adults with body 
mass index>25 kg/m2 and diagnosis of T2D in the past 
3 years and randomise them to a tailored DEW or a 
DE programme. Participants will attend measurement 
appointments at a local general practitioner practice or 
research centre at baseline, 6 and 12 months. The primary 
outcome is 12- month change in glycated haemoglobin. 
The effect of the intervention on the primary outcome will 
be estimated and tested using a linear regression model 
(analysis of covariance) including randomisation group 
and adjusted for baseline value of the outcome and the 
randomisation stratifiers. Participants will be included 
in the group to which they were randomised, under the 
intention- to- treat principle. Secondary outcomes include 
6- month and 12- month changes in body weight, body 
fat percentage, systolic and diastolic blood pressure 
and lipid profile; probability of achieving good glycaemic 
control; probability of achieving remission from diabetes; 
probability of losing 5% and 10% body weight and 
modelled cardiovascular risk (UKPDS). An intention- to- treat 
within- trial cost- effectiveness analysis will be conducted 
from NHS and societal perspectives using participant- 
level data. Qualitative interviews will be conducted with 
participants to understand why and how the programme 
achieved its results and how participants manage their 
weight after the programme ends.
Ethics and dissemination Ethical approval was received 
from East of Scotland Research Ethics Service on 15 May 
2018 (18/ES/0048). This protocol (V.3) was approved 
on 19 June 2019. Findings will be published in peer- 
strengths and limitations of this study
 ► This trial will provide robust evidence of the clinical 
and cost- effectiveness of a scalable tailored diabe-
tes education and behavioural weight management 
programme versus diabetes education alone in 
adults with a recent diagnosis of type 2 diabetes.
 ► If shown to be cost- effective, the intervention being 
evaluated could be readily integrated into existing 
UK care pathways and delivered to large numbers 
of people.
 ► The behavioural programme is already widely avail-
able across many countries and this model of care 
could be readily adopted across healthcare services 
internationally.
 ► This trial only includes follow- up at 6 and 12 months 
and longer term data may be needed to understand 
the longer term impact of these programmes.
 ► Consent has been obtained to follow- up participants 
through national registries and medical records for 
up to 15 years.
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reviewed scientific journals and communicated to other stakeholders as 
appropriate.
trial registration number ISRCTN18399564.
bACkground
The treatment of diabetes and related complications 
(eg, cardiovascular disease, amputation, kidney failure) 
uses approximately 10% of the UK NHS budget.1 This is 
predicted to rise to 17% in 2035 as the number of people 
with diabetes in the UK rises to 6.25 million, of which 
5.6 million cases will be adults with type 2 diabetes (T2D).1 
Adults who are living with T2D are at increased risk of 
developing physical and mental health comorbidities 
and have reduced quality of life and shorter life expec-
tancy.2 3 There are considerable social and economic costs 
to the individual living with diabetes as well as to wider 
society.1 2 4
While T2D is typically characterised as a progres-
sive, irreversible condition, there is evidence of 
remission in patients losing weight through bariatric 
surgery5 6 or closely supervised very- low- calorie formula 
diets.7 8 However, many patients with T2D may be unsuit-
able for or unwilling to undergo these interventions and, 
given their high cost and reliance on specialists, they are 
unlikely to be widely adopted in the NHS in the near 
future. Partial or complete remission of T2D has also 
been observed following smaller weight losses achieved 
through behavioural interventions.9 Moreover, even 
without remission, weight loss and behaviour change can 
lead to improvements in health outcomes in people who 
have diabetes. We have shown that losing a moderate 
amount of weight or making healthy behaviour changes 
(eg, increasing physical activity, reducing alcohol, energy 
and fat intake) in the first year after diagnosis can reduce 
the likelihood of stroke or heart attack in the next 5–10 
years10–12 and increase the likelihood of achieving remis-
sion at 5 years.13
The Look AHEAD trial demonstrated that intensive 
specialist- led behavioural programmes could lead to 
weight loss and reductions in cardiovascular risk factors 
over 8- year follow- up.14 However, there are currently 
insufficient resources in the UK NHS to provide inten-
sive, specialist- led behavioural programmes to 3.2 million 
individuals who have T2D and the additional 200 000 
individuals who are diagnosed each year. Instead, current 
guidelines focus on structured diabetes education (DE) 
and dietary advice,15 which is cheaper and scalable but 
has small, short- term effects on weight and glycaemia, 
and relatively poor uptake.16–18 A recent systematic review 
found that supportive behaviour change programmes 
(with ≥11 hours of contact time) achieve greater reduc-
tions in weight and glycated haemoglobin (HbA1c) 
than structured education without additional support 
(≤10 hours).17 Integrating effective but scalable behaviour 
change programmes into care pathways for T2D could 
potentially improve patients’ glycaemic control and 
related risk factors and reduce complications. This would 
improve health and quality of life for people living with 
diabetes and reduce the burden of diabetes on health-
care resources.
We have previously shown that commercial open- group 
behavioural weight management programmes, such as 
WW (formerly Weight Watchers) or Slimming World, 
offer a scalable and cost- effective way to help people lose 
weight and reduce risk of diabetes.19–22 A randomised 
trial in the USA showed that a combination of WW classes 
and remote dietary counselling achieved greater weight 
losses and reductions in HbA1c than standard care over 
1 year in people with diabetes.23 A quarter of participants 
randomised to this programme achieved good glycaemic 
control (HbA1c below 53 mmol/mol) at 12 months 
compared with 14% of those receiving standard care. 
In the UK, a similar intervention has been developed 
for use in the NHS that combines referral to WW with 
NICE- compliant DE and dietary advice. However, this 
programme is unlikely to be widely commissioned without 
robust evidence of cost- effectiveness. The proposed trial 
will provide reliable evidence on the relative effective-
ness and cost- effectiveness of a tailored diabetes educa-
tion and behavioural weight management programme 
(DEW) versus DE, for people with a recent diagnosis of 
T2D (≤3 years).
objECtIvEs
Primary objective
To evaluate the effect of tailored DEW versus DE on HbA1c 
at 12 months in adults with a recent diagnosis of T2D.
secondary objectives
To evaluate the effect of DEW versus DE on:
 ► body weight, body fat percentage, blood pressure, 
lipid profile and modelled 10- year cardiovascular risk 
at 6 and 12 months
 ► probability of achieving clinically significant weight 
loss, good glycaemic control or diabetes remission at 
6 and 12 months
 ► changes in diet and physical activity at 6 and 12 
months
 ► psychosocial factors associated with successful weight 
control at 6 and 12 months.
To evaluate the within- trial cost- effectiveness of DEW vs 
DE.
To assess the extent to which the two programmes reach 
the target population.
To explore participant and practitioner experiences 
of the two programmes and the extent to which these 
programmes meet their needs.
To clarify causal mechanisms and identify contextual 
factors associated with variations in outcome.
To identify barriers and facilitators to maintenance 
of weight management behaviours after treatment 
cessation.
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Figure 1 Participant flow diagram.
MEthods And AnAlysIs
trial design
This is a pragmatic, randomised, single- blind, parallel 
group, two- arm, superiority trial. Participants will be 
randomised to either the tailored DEW or to DE. Block 
randomisation will be used with a 1:1 allocation stratified 
by sex and duration of diabetes (figure 1).
study setting
Research active primary care practices which currently 
refer patients with T2D (≤3 years duration) to local struc-
tured DE (Diabetes and Education Self- Monitoring for 
Ongoing and Newly Diagnosed (DESMOND)) and have 
active WW groups in the local community.
Participants
Participants will be 576 adults with overweight or obesity 
who have a diagnosis of T2D in the past 3 years.
Inclusion criteria
 ► Body mass index≥25 kg/m2.
 ► Age≥18 years.
 ► Diagnosis of T2D within the previous 36 months 
(confirmatory blood test will not be required).
 ► Capable of giving informed consent.
 ► Have a good understanding of the English language 
(study materials are not tailored to support non- 
English language speakers).
 ► Willing to be randomised.
 ► Willing to attend follow- up visits at a local partici-
pating general practitioner (GP) practice or research 
centre.
Exclusion criteria
 ► Using insulin.
 ► Previous/planned bariatric surgery.
 ► Current/planned pregnancy.
 ► Current diagnosis of eating disorder.
 ► Already received a structured DE programme.
 ► GP considers unsuitable.
 ► Participation in another structured behaviour change 
programme for diet and/or physical activity within 
the past 3 months.
IntErvEntIons
 tailored diabetes Education and Weight management
The tailored DEW programme was developed and is 
delivered by WW. It lasts 6 months and is overseen by a 
registered dietitian with experience in diabetes, diet and 
behaviour counselling and specific training in the stan-
dard WW programme.
 Structured DE
The structured DE programme is delivered remotely 
(video conferencing/telephone) on a 1:1 basis by the 
registered dietitian over two education sessions, 3–5 
weeks apart (total time 1 hour 30 min, divided between 
two calls). It covers a standardised QISMET- accredited 
core curriculum but can then be adapted for the indi-
vidual’s needs. Additional self- help education materials 
to support the curriculum will be available online and 
are delivered to all participants via email or mail at the 
patient’s preference. These materials may be minimally 
tailored to the individual participant. Information on 
the materials can be found at www. weightwatchers. com/ 
4 Ahern AL, et al. BMJ Open 2020;10:e035020. doi:10.1136/bmjopen-2019-035020
Open access 
uk/ live- well- diabetes. During the education sessions, 
materials on goal setting, understanding diabetes, the 
glycaemic index, carbohydrates, physical activity and 
weight management are reviewed.
 Behavioural programme
The behavioural weight management component 
consists of free membership of WW for 6 months. This 
includes attendance at weekly in- person group meetings 
(30–40 min) held at a variety of times in a range of local 
community venues. These are open- group meetings (new 
people may join or leave the group at any time) and are 
led by a coach (trained lay person with experience of the 
programme). Meetings include a confidential weigh in 
with the coach and a 30 min interactive education session 
led by the coach which includes advice on diet, physical 
activity and positive mindset, using behavioural strategies 
(eg, goal setting, self- monitoring, problem solving, modi-
fying the personal food environment and relapse preven-
tion). Peer support is available from coaches and other 
group members. Participants can be accompanied by a 
friend, relative or carer. Participants will also have access 
to the WW app, online digital tools and standard mate-
rials such as recipe booklets, physical activity guidance 
and meal trackers for the duration of the intervention. 
Participants can contact their coach for support/advice 
between meetings via an online chat function.
 Participant engagement
Once a referral is received, the registered dietitian 
will telephone the participants, welcome them to the 
programme, sign them up to a local WW meeting and 
arrange the first education session. Participants are also 
given an information sheet with details of how to contact 
the dietitian directly. A closed social media support group 
will be formed and all participants will be encouraged to 
join if they wish to do so. Activity on the group forum 
will be monitored and supported by the registered dieti-
tian. Each week, the dietitian will contact 2–5 participants 
(selected at random from those who have participated in 
the programme for longer than 3 months) via the social 
media group or phone. Participants can also contact the 
dietitian proactively during the intervention period for 
additional remote support where needed, but they will be 
encouraged to do so via the social media group in the first 
instance. If participants miss four or more WW standard 
in- person meetings, their local coach will call to help the 
individual return to the programme.
 diabetes education
We will recruit from Clinical Commissioning Groups 
(CCGs) where the commissioned standard care DE is 
the DESMOND programme.16 18 This is a structured DE 
programme for people with a recent diagnosis of T2D (≤3 
years since diagnosis). Participants can attend 6 hours of 
structured self- management group education, covering: 
thoughts and feelings about diabetes; understanding 
diabetes and glucose—what happens in the body; 
understanding risk factors and complications associated 
with diabetes; understanding monitoring and medication; 
how to take control—food choices and physical activity 
and planning for the future. The structured education is 
delivered in 1 day or 2 half days by two trained healthcare 
professionals in local healthcare or community venues. 
Sessions are delivered in groups of up to 10 participants, 
and participants can bring a friend or partner with them. 
The education sessions are supported by specially devel-
oped resources.
outcomes
 Primary outcome
The 12- month change from baseline in HbA1c.
 Secondary outcomes
The 6- month change from baseline in HbA1c.
The 6- month and 12- month changes from baseline in 
body weight, body fat percentage, systolic and diastolic 
blood pressure, total cholesterol, high- density lipopro-
tein cholesterol and low- density lipoprotein cholesterol.
Good glycaemic control (HbA1c <53 mmol/mol) at 6 
and 12 months.
Remission from diabetes (HbA1c <48 mmol/mol and 
without glucose- lowering medication for ≥2 months) at 
6 and 12 months.
Weight loss ≥5% and ≥10% of initial body weight at 6 
and 12 months.
Modelled cardiovascular risk (UKPDS) at 12 months.
Behavioural and psychosocial outcomes
The 6- month and 12- month changes from baseline in 
objectively measured physical activity (accelerometry), 
self- reported physical activity, objective marker of fruit 
and vegetable intake (plasma carotenoids) and self- 
reported dietary intake.
The 6- month and 12- month changes from baseline, 
adjusted for baseline, in dietary restraint, control over 
food cravings, emotional eating, self- regulatory skills, 
social support and diabetes- related quality of life.
Health economic outcomes
Detailed micro- costing of DEW and DE.
Health and social care resource use over 12 months 
(medical notes, registry data, resource use questionnaire).
Self- reported out- of- pocket costs and lost productivity 
(eg, due to days off work, up to 12 months).
The 12- month quality- adjusted life years (QALYs) 
based on Health- Related Quality of Life (HRQoL) 
(EQ- 5D- 5L)24 25 and capability/well- being (ICECAP- A).26 27
Total and incremental costs from NHS and societal 
perspectives; incremental net (monetary) benefit; incre-
mental cost- effectiveness and cost- utility ratios; value of 
information estimates.
 Uptake and adherence
Number and characteristics of participants who:
 ► are offered the opportunity to participate in the trial.
 ► enrol in the trial
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Figure 2 Schedule of enrolment, interventions and 
assessments.
 ► attend the intervention.
 ► adhere to the intervention (including specific inter-
vention components).
A detailed protocol for process evaluation will also be 
developed.
visits and measurements
 Visit schedule
Participants will be asked to attend measurement appoint-
ments at a participating primary care practice or research 
centre at 0, 6 and 12 months. Details of measures at each 
assessment are summarised in figure 2. Participants will 
be reimbursed for reasonable travel expenses and given 
an honorarium for attending measurement appoint-
ments (£10 for baseline and 6- month visits, £30 for the 
12- month visit). Honoraria for assessment attendance are 
not dependent on intervention attendance/completion.
 Anthropometric measures
Anthropometric measurements will be made at partic-
ipating primary care practices or research centres by 
research- trained healthcare professionals (hereafter 
‘research nurses’) blind to intervention allocation, in 
line with standardised operating procedures. Participants 
will be asked to remove shoes and heavy clothing items. 
Height will be measured in centimetres using a mounted 
stadiometer (make and model dependent on practice). 
Where possible, weight (kg) and body fat percentage will 
be measured using a calibrated Tanita segmental body 
composition analyser (Tanita Ltd; MA Tokyo, Japan; 
model dependent on practice) which will be provided to 
practices by the research team. Where we have an insuf-
ficient number of Tanita scales to measure body fat at 
a practice, we will measure weight (kg) only using cali-
brated electronic scales (model dependent on practice). 
To maximise the number of participants for whom we can 
measure body fat, we will prioritise the use of Tanitas at 
large practices with a large number of eligible patients, 
and ClinicalResearch Networks (CRN)- led practices (as 
CRN nurses can transport the Tanita scales to numerous 
practices). Blood pressure will be measured three times 
in a resting state using a calibrated OMRON automatic 
blood pressure monitor (OMRON Healthcare UK, Milton 
Keynes, UK; model dependent on practice).
If a research nurse is not available to conduct follow- up 
assessments, assessments may be conducted by trained 
research centre staff. If participants are unable to attend 
follow- up appointments at a participating practice, 
the research team may offer appointments at the local 
hospital or research centre, or home visits. Participants 
who are unable or unwilling to attend a visit will be asked 
to provide a self- measured weight. All other participants 
will also be asked for a self- measured weight at the time of 
appointment booking to enable us to quantify the degree 
of misreporting of self- measured weights.
 Biochemical measures
Participants will be asked to provide a blood sample for 
the measurement of HbA1c, lipid profile and carotenoids. 
If possible, this sample will be taken at the practice at 
the same time as the anthropometric measurements. 
Blood samples will be collected in three tubes labelled 
with an anonymised barcode (4.9 mL serum tube for lipid 
profile, 2.6 mL Ethylenediaminetetraacetic acid (EDTA) 
tube for HbA1c, 4.9 mL and lithium heparin (LH) tube 
for carotenoids). The LH tube is light sensitive, so it will 
be wrapped in foil to avoid degradation. Samples will be 
placed in a Royal Mail Safebox and posted via first- class 
mail to the central laboratory for analysis. Each sample 
is stable for up to 3 days at room temperature. Plasma 
samples for analysis of carotenoids will be frozen and 
analysed in batches.
 Behavioural measures
Physical activity
Physical activity will be measured objectively using a 
triaxial accelerometer (Axivity AX3, Newcastle, UK) 
which measures raw acceleration (m/s2). Participants 
will be asked to wear the accelerometer on their non- 
dominant wrist continuously for seven consecutive days 
and nights. The device is small, light and waterproof and 
is worn like a watch. It does not need to be taken off while 
showering, bathing or swimming.
At the baseline visit, the nurse will take the participant 
through the accelerometer instruction sheet. They will 
demonstrate to the participant how they should wear 
the monitor on their wrist. The nurse will also ensure 
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Table 1 Questionnaires administered in the GLoW trial
Domain Measure Time point
Demographics Bespoke questionnaire 
based on PROGRESS- 
Plus32
Baseline
Health- related 
quality of life
EQ- 5D- 5L24 25 All
Capability/well- 
being
ICECAP- A26 27 All
Diabetes- related 
quality of life
Audit of Diabetes 
Dependent Quality of 
Life35
All
Health/social care 
use
Bespoke resource use 
questionnaire
All
Food cravings Control of Eating 
Questionnaire36
All
Dietary restraint Three Factor Eating 
Questionnaire—Restraint 
subscale37
All
Binge eating The Binge Eating Scale38 
39
All
Dietary intake Food Frequency 
Questionnaire31
All
Physical activity Recent Physical Activity 
Questionnaire29 30
All
Intervention 
adherence
Bespoke questionnaire 6 months
GLoW, Glucose Lowering through Weight management.
that the timing of the monitor and return is feasible for 
the participant. The study team will initialise the accel-
erometer and will post it out to the participant with the 
instruction sheet. The participant will wear the monitor 
for 7 days and nights and will complete an activity log. For 
the 6- month and 12- month visits, accelerometers will be 
mailed out to participants. At the end of 7 days, the partic-
ipant will be asked to post the device back to the research 
centre using prepaid, preaddressed materials. Trained 
staff will download the data from the accelerometer and 
check it to ensure the integrity of the data recording. 
This method has been used in large- scale epidemiological 
studies including the UK Biobank study in 100 000 indi-
viduals.28 Data will be analysed using established methods 
used in UK Biobank. The outcome variables of interest 
are vector magnitude, a measure of total physical activity 
and intensity distribution, from which duration of time in 
different levels of physical activity can be inferred.
Self- reported physical activity will be measured using 
the Recent Physical Activity Questionnaire, a validated 
measure of four domains of physical activity (leisure time, 
occupation, commuting and domestic life) that has been 
used in a number of intervention studies and large- scale 
epidemiological studies.29 30 This will be administered as 
part of the self- report questionnaires.
Diet
Plasma carotenoids will be measured as an objective 
marker of fruit and vegetable intake. Self- reported dietary 
intake will be measured at each time point using a version 
of the previously validated EPIC Food Frequency Ques-
tionnaire31 that has been adapted for a 6- month recall 
period. This will be administered as part of the self- report 
questionnaires.
Self-report questionnaires
Participants will complete a demographics questionnaire 
at baseline based on Progress- Plus32 factors (place of 
residency, race/ethnicity, occupation, gender/sex, reli-
gion, education, socioeconomic status, social capital, age, 
disability, relationship status, caring responsibilities, car 
ownership, access to the internet).
Self- reported behavioural and psychosocial measures 
will be collected via validated self- report questionnaires 
that can be completed on paper or online, at the partic-
ipant’s preference. A full list of questionnaires can be 
found in table 1.
 Intervention adherence
Adherence data for the tailored DEW (including atten-
dance at weekly WW meetings and remote education 
sessions, and use of online tools) will be collected by WW 
as part of an established system for NHS contracts. Self- 
reported intervention adherence for both programmes 
will also be collected via a self- report questionnaire.
 Medical notes review
Healthcare resource use will be obtained for all partici-
pants via medical notes review and registry data. Primary 
care records will be used to extract numbers of visits to 
the GP and community healthcare workers (defined as 
any primary or community- based health worker such as 
nurse and allied health professional contacts noted in 
the patient’s record) and prescribed medications. Last 
recorded weight, HbA1c value, smoking status and diabetes 
status will also be extracted. This will help to minimise 
missing data from missed assessment appointments.
The notes review will be carried out at each study visit 
and following the end of the study by a research nurse 
blind to intervention allocation.
 ► Baseline visit: notes review to cover the 3 months prior 
to study start
 ► 6- month visit: notes review to cover from baseline up 
to 6 months.
 ► 12- month visit: notes review to cover from 6 months 
to 12 months
We will obtain consent to conduct future notes reviews 
after the study has completed (up to 15 years poststudy) 
for future studies of long- term outcomes.
 Administrative and registry data
We will obtain consent at baseline for future collec-
tion of administrative and registry data on health event 
and healthcare usage information (up to 15 years post-
study). Outcomes will include hospital episode statistics, 
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cardiovascular events, stroke, myocardial infarction, 
cancer and death and will be obtained from NHS digital, 
the Healthcare Quality Improvement Partnership and 
the National Cancer Registration and Analysis Service. 
This will allow us to evaluate the longer term impact of 
these programmes on diabetes- related and weight- related 
morbidity and mortality.
 Qualitative interviews
Around the time of the 6- month follow- up, we will 
conduct semi- structured interviews with participants 
from both intervention arms (n≥26). Participants will be 
recruited in a 2:1 ratio (DEW:DE), as we are interested 
in comparing the experience of the two groups, but 
we expect the group receiving the DEW programme to 
provide the richest data on the experiences of weight loss 
and weight loss maintenance. Participants will be purpo-
sively sampled (demographic characteristics, programme 
attendance/adherence, weight change). We will also 
conduct interviews with treatment providers (n≥12) to 
understand their experience of delivering the interven-
tion. Interviews will be conducted by a trained research 
associate and audio recorded.
Questions will focus on exploring:
 ► How did participants and practitioners experience 
the programme and its components: (1) education; 
(2) WW meetings; (3) digital tools and (4) remote 
dietetic counselling?
 ► What were the causal mechanisms and contextual 
factors that were associated with different outcomes?
 ► What were the needs of participants at the end of the 
programme?
 ► What were the facilitators and barriers to maintaining 
behavioural change?
recruitment and enrolment
 Recruitment of practices
Primary care practices will be identified and recruited by 
the CRN. Participating practices must be currently refer-
ring patients with a recent diagnosis of T2D to structured 
DE (DESMOND) as part of standard practice and should 
have active WW meetings in the local area. They should 
also be research active with the capacity to recruit and 
follow- up participants. The CRN will attempt to recruit 
practices from diverse areas using known characteristics 
of the practice population to enable recruitment of a 
sample broadly representative of the target population 
(UK adults with overweight and obesity and who have a 
recent diagnosis of T2D).
 Patient identification
Eligible patients will be identified through electronic 
searches of primary care records and waiting lists for DE. 
GPs will write to all potentially eligible patients inviting 
them to participate. This letter will include a participant 
information sheet and details of how to contact the study 
team at the research centre. Participants will also receive 
opportunistic invitations during routine consultations via 
an invitation letter and participant information sheet to 
take home with them. Pop- up alerts on patient records 
(triggered by diagnosis or attempted referral to DE) will 
be implemented to facilitate opportunistic recruitment. 
To boost enrolment, advertisements will also be placed in 
local pharmacies, news media and other relevant settings.
 Enrolment
Patients willing to participate will be asked to contact the 
research centre for more information. This can be by 
telephone, email or reply slip. Research centre staff will 
answer any questions and conduct a telephone screening. 
If patients are eligible and willing to participate, the 
research staff will check that they have received the partic-
ipant information sheet (sending another if they have 
not) and arrange a baseline assessment with the research 
nurse at a local participating practice or research centre.
At the baseline visit, the research nurse will take 
informed consent. This will include ensuring that partici-
pants have read the information sheet and had the oppor-
tunity to ask questions. They will also confirm eligibility, 
including an objective measure of height and weight, 
before taking the rest of the baseline measurements. At 
the end of each day, the research nurse will email the 
study coordinator a list of participants who have formally 
enrolled on the trial.
randomisation
 Randomisation sequence
Participants will be allocated to one of the two inter-
vention arms in a 1:1 allocation using individual- level 
blocked randomisation stratified by sex (men, women) 
and duration of diabetes (<1 year, 1–3 years) with a block 
size of 6. The randomisation sequence will be computer- 
generated by the trial statistician and the randomisation 
process implemented by the data manager. The sequence 
will be unknown to all other personnel, including study 
coordinators, outcome assessors and investigators.
 Method of implementing the allocation sequence
When participant eligibility has been confirmed at the 
baseline visit, the practice will inform the study coordi-
nator. The study coordinator will enter the participant’s 
details into the trial database which will automatically 
assign an intervention to the participant.
The study coordinator (or member of their team) will 
write to the participant to inform them of their interven-
tion allocation and will also inform the participant’s GP. 
The study coordinator or the GP (depending on prac-
tice and intervention allocation) will also send a referral 
form to the intervention provider, giving the details of the 
participant who has been referred to them.
 Blinding
Given the nature of the intervention, it is not possible to 
blind participants to their intervention group. GPs will be 
informed of the intervention allocation and participants 
will be allowed to discuss the intervention with their GP, as 
they would outside a trial scenario. However, participants 
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will be asked not to reveal their intervention group to 
outcome assessors (ie, research nurses taking measure-
ments). The trial statistician and the investigators will be 
blinded to intervention allocation until the database is 
locked and the primary analysis is complete.
statistics and data analysis
 Sample size calculation
The primary outcome is 12- month change from baseline 
in HbA1c. Based on data from a previous trial in adults 
with a recent diagnosis of T2D,33 we assumed a 16 mmol/
mol SD, a 0.8 correlation between baseline and follow- up 
and 25% attrition. In a US trial of a similar intervention in 
people with T2D of any duration, a difference of 4 mmol/
mol was observed between intervention (−3 mmol/mol) 
and control (+1 mmol/mol) at 12 months.23 We need 576 
participants to detect a difference between randomised 
groups of 3 mmol/mol HbA1c with 90% power at a 5% 
significance level.
 Statistical analysis plan
A detailed statistical analysis plan will be developed and 
signed off by the Trial Steering Committee (TSC) prior 
to analysis. Participants will be analysed in the group to 
which they were randomised, based on the intention- to- 
treat principle. The intervention effect, representing the 
baseline- adjusted difference in change from baseline to 
12 months in HbA1c between the intervention and control 
group, will be estimated using a linear regression model 
including randomisation group, baseline value of HbA1c 
(ie, analysis of covariance (ANCOVA)) and the randomi-
sation stratifiers (sex, duration of diabetes). The missing 
indicator method34 will be used to ensure inclusion of 
participants with a missing baseline value of HbA1c. Partic-
ipants with missing values of HbA1c at 12 months will be 
excluded (ie, a complete- case analysis). If there are >5% 
of participants with missing values of HbA1c at 12 months, 
a sensitivity analysis will be performed using multiple 
imputation by chained equations; full details of this anal-
ysis will be provided in the statistical analysis plan.
Continuous secondary outcomes will be analysed using 
the method described earlier. Binary secondary outcomes 
will be analysed using a logistic regression model including 
randomisation group and the randomisation stratifiers.
For the primary outcome, effect modification by (1) 
sex, (2) index of multiple deprivation (high, low), (3) 
educational qualification (below postsecondary, postsec-
ondary and above postsecondary) and (4) duration of 
diabetes (<1 year; 1–3 years) will be tested using an F- test 
of the relevant multiplicative interaction parameter in 
the ANCOVA model. If the p value for a particular inter-
action is <0.05, then the intervention effect and 95% CI 
will be estimated within the relevant subgroups.
 Economic evaluation
A detailed health economics analysis plan will be devel-
oped and signed off by the TSC prior to analysis. An 
intention- to- treat within- trial cost- effectiveness analysis 
will be conducted from both the NHS and the societal 
perspectives using participant- level data. Benefits will 
be measured by changes in HbA1c at 12 months for the 
primary analysis and changes in weight (kg), HRQoL 
(EQ5D- 5L), capability/well- being (ICECAP- A) and 
QALYs at 12 months for the secondary analyses. Resource 
use data will be extracted from patient- completed ques-
tionnaires and validated with primary care notes review. 
Unit costs will be extracted from standard NHS cost data-
bases and publications (eg, NHS Reference Costs). Costs 
and benefits will be left undiscounted as follow- up is only 
1 year. If required and appropriate, missing data will be 
imputed using recognised techniques such as multiple 
imputation. Descriptive statistics for resource use, total 
costs, HRQoL and capability/well- being at 1 year as well 
as incremental cost- effectiveness and cost- utility ratios 
and incremental net (monetary) benefit measures will 
be reported. We will undertake deterministic and prob-
abilistic sensitivity analyses, presenting the results of the 
latter as cost- effectiveness acceptability curves. Value of 
information analysis will quantify the value of reducing 
the decision uncertainty which will inform whether 
further research is worthwhile following completion of 
this study, and if so on which parameters.
 Qualitative evaluation
Qualitative analyses will explore how the programmes 
were implemented; participant and provider percep-
tions of the extent to which the programmes met patient 
needs and factors participants and providers regarded 
as causally significant. Analyses will also explore the key 
challenges anticipated around treatment cessation and 
weight loss maintenance, and the value attached to the 
possibility of freedom from or reduction in medication 
and the concept of ‘remission’.
Recordings will be transcribed by an experienced 
external agency and checked for accuracy by the research 
team. Verbatim transcripts will be coded using NVivo soft-
ware, retaining a focus on narrative sequences and tran-
sitions as well as salient themes. A dual coding approach 
will be used: a first inductive round based on emerging 
themes relating to the research questions and a second 
round sensitised by quantitative findings. In the first 
inductive stage, open codes will be generated based on 
line- by- line scrutiny of verbatim transcripts uploaded into 
NVivo. Inconsistencies between coders will be resolved 
through discussion. Patient and public involvement (PPI) 
representatives will assist with the analysis of qualitative 
data; this will include coding a subsample of transcripts 
following training, and ensuing dialogue.
trial steering Committee
The TSC will provide overall supervision for the GLoW 
Trial on behalf of the Trial Sponsors (NHS Cambridgeshire 
and Peterborough CCG, University of Cambridge) and 
Trial Funder (NIHR Clinical Commissioning Facility) 
and ensure that the project is conducted to the rigorous 
standards set out in the UK Policy Framework for Health 
9Ahern AL, et al. BMJ Open 2020;10:e035020. doi:10.1136/bmjopen-2019-035020
Open access
and Social Care Research and the Guidelines for Good 
Clinical Practice. The TSC will provide advice to the 
investigators on all aspects of the trial and will review 
and agree the trial protocol, the statistical analysis plan 
and any amendments to the protocol. The TSC will 
be chaired by Professor Andrew Farmer (University 
of Oxford). Independent members include Professor 
Lucy Yardley (University of Southampton), Dr Thomas 
Fanshawe (University of Oxford), Dr Edel Doherty (NUI 
Galway), Mr Graham Rhodes (PPI representative) and Ms 
Hazel Patel (PPI representative). This is a low- risk trial 
in which participants in both trial groups are referred to 
accredited education programmes. There are no rules for 
early stopping and participants and GPs are not blind to 
intervention allocation. Thus a separate data monitoring 
committee is not deemed to be necessary.
Patient and public involvement
PPI informs the design, management, analysis and dissem-
ination of the GLoW study. The initial ideas and research 
proposal were reviewed by three members of Fakenham 
Weight Management Service and six members of the 
University of Cambridge PPI Panel. A PPI representative 
(JB) is a member of our investigator team and has contrib-
uted to the design of the protocol. She will also contribute 
to designing and delivering PPI training, preparing ethics 
and R&D submissions, co- authoring journal articles and 
the final report, disseminating findings to a wide range of 
audiences and supporting other PPI members. Two PPI 
representatives are members of the TSC. They will review 
the final study reports and contribute to the writing of 
specific sections, such as the lay summary.
To maximise participant engagement and retention 
and minimise burden, PPI representatives review the 
content, design and delivery of participant- facing mate-
rials. PPI representatives will also support the design of 
the qualitative interview schedule and the analysis and 
interpretation of qualitative data. Including PPI perspec-
tives in plans for dissemination will ensure that we access 
an appropriate range of audiences and communicate 
messages effectively. PPI representatives will advise on 
content and methods of dissemination and will review 
public facing documents such as newsletters and press 
releases.
PPI representatives will be reimbursed for their time 
and expenses in a timely manner, and tailored PPI 
training will be provided to suit the specific needs of the 
individuals and their role.
Ethics and dissemination
The MRC Epidemiology Unit has an over- arching data 
management policy (DMP) that encompasses the stan-
dards and processes applied to all research and oper-
ational activities in the Unit. A study- specific data 
management plan, based on this DMP, details how 
data will be collected, stored, transferred, accessed and 
archived. The principal investigators (PIs) will ensure that 
all data generated, stored and shared from this trial will 
be handled in compliance with the DMP and the General 
Data Protection Regulations.
All specified analyses will be written up as scientific 
papers and submitted for publication in peer- reviewed 
open- access journals. Members of the research team 
will be involved in reviewing drafts of the manuscripts, 
abstracts and any other publications arising from the trial. 
The PIs will have final approval on all publications and 
any press release, where appropriate. Authorship will be 
determined using ICMJE criteria. On publication of the 
main findings, participants will be sent a newsletter that 
describes the results and gives details of whom to contact 
to ask questions or obtain further information. Newslet-
ters will be prepared with input from PPI representatives. 
Where appropriate, we will communicate our findings to 
local and national stakeholders via tailored summaries of 
the key findings and by presentations at meetings of local 
and national networks. Representatives from these groups 
will be involved in our research throughout and will 
support us in identifying opportunities for dissemination.
trial status
This protocol (V.3) included additional strategies to boost 
recruitment and was approved on 19 June 2019. Recruit-
ment for the trial began on 18 July 2018 and is expected 
to close in August 2020.
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